Last reviewed · How we verify
Ketensin (KETANSERIN)
At a glance
| Generic name | KETANSERIN |
|---|---|
| Drug class | ketanserin |
| Target | 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Hypertensive disorder
Common side effects
Key clinical trials
- Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects (PHASE1)
- Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PHASE1)
- Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants (PHASE1)
- The Neurobiological Effect of 5-HT2AR Modulation (PHASE1)
- Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness (PHASE1)
- Effect of Ketanserin After LSD Administration (PHASE1)
- Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study) (EARLY_PHASE1)
- Ketanserin Effects on Peripheral Temperature and Lactate (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketensin CI brief — competitive landscape report
- Ketensin updates RSS · CI watch RSS